Why the study?
Do different drug classes (ACEi, ARB, ARNI, MRA, beta-blockers, SGLT2i) reduce hospitalization or mortality in patients with HFpEF and HFmrEF?
Population
20 633 patients with HF and an ejection fraction of 40% or more across 19 RCTs
Comparison
ACE inhibitors, ARBs, ARNIs, MRAs, beta-blockers, and SGLT2 inhibitors vs placebo or each other
Design
Systematic review and bayesian network meta-analysis of randomized clinical trials
Authors
Loading...
May support SGLT2i prioritization in HFpEF/HFmrEF; extends comparative evidence where direct RCTs remain sparse.
Do different drug classes (ACEi, ARB, ARNI, MRA, beta-blockers, SGLT2i) reduce hospitalization or mortality in patients with HFpEF and HFmrEF?
SGLT2 inhibitors, ARNIs, and MRAs significantly reduce the risk of heart failure hospitalization in patients with HFpEF and HFmrEF, with SGLT2 inhibitors being the optimal drug class.
Xiang et al. (2022) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: